COMMUNIQUÉS West-GlobeNewswire

Organogenesis Applauds CMS’s Significant Step In Payment Reform
03/11/2025
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond CANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- [...]
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
03/11/2025
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray) Oral presentation to report results from real world data on the [...]
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
03/11/2025
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP [...]
D5 Health - Personalized Longevity Clinic Opens Its Doors in Raleigh, NC
03/11/2025
Innovative Clinic Offers Personalized Health Solutions to Optimize Vitality and Longevity Raleigh, NC, Nov. 03, 2025 (GLOBE NEWSWIRE) -- D5 Health , a personalized longevity clinic in Raleigh, is thrilled to announce [...]
A Rockstar Puppet and a Life-Saving Message: NMDP Launches New Awareness Campaign to Help More Patients Receive Cell Therapy
03/11/2025
High-energy public service announcement uses music and humor to start discussions about blood cancer MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NMDP SM , a global nonprofit leader in cell therapy, today announced [...]
Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025
03/11/2025
LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed company dedicated to building a long-term strategic treasury [...]
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
03/11/2025
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc . (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update
03/11/2025
Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 [...]
Zelluna ASA – Contemplates private placement
03/11/2025
Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR [...]
Legal Steroids for Bulking, Cutting, Strength from CrazyBulk: Best Selling Legal Steroid Alternatives for Muscle Growth and Bodybuilding in 2025
03/11/2025
Crazy Bulk's Introduces Best Legal Steroid Alternatives Safe and Most Popular Legal Steroids for Muscle Building and Cutting supplements in 2025. It Help to Boost testosterone, and improve muscle growth, strength, and [...]
NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
03/11/2025
Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, [...]
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
Two oral and seven poster presentations further support the CARVYKTI ® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., [...]
Rendever Receives Nearly $4.5 Million in NIH Funding to Overcome Social Isolation for Older Adults while Supporting Caregivers
03/11/2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rendever , the company leading the industry in immersive technology for aging, has secured nearly $4.5 million in grant funding from the National Institutes of Health (NIH) to [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03/11/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 novembre 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting
03/11/2025
SOMERVILLE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced three presentations of new [...]
Solana Company (NASDAQ: HSDT) Releases Investor Update
03/11/2025
NEWTOWN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed digital asset treasury dedicated to acquiring and holding Solana (SOL), today announced the [...]
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a [...]
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
03/11/2025
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its [...]

Pages